Prulifloxacin
From Wikipedia, the free encyclopedia
Please help improve this article or section by expanding it. Further information might be found on the talk page or at requests for expansion. (March 2008) |
Prulifloxacin
|
|
Systematic (IUPAC) name | |
? | |
Identifiers | |
CAS number | ? |
ATC code | J01 |
PubChem | |
Chemical data | |
Formula | C21H20FN3O6S |
Mol. mass | 461.463403 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | By esterases, to ulifloxacin |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | Oral |
Prulifloxacin (INN) is a broad-spectrum fluoroquinolone antibiotic. It is a prodrug, and is metabolized in the body to the active compound ulifloxacin. Prulifloxacin has a long half-life and may therefore be taken only once a day.[1]
In clinical trials, prulifloxacin appeared as effective as ciprofloxacin, co-amoxiclav or pefloxacin in the treatment of bronchitis exacerbations or lower urinary tract infections. It was tolerated as well as ciprofloxacin.[1]
[edit] References
- ^ a b Keam SJ, Perry CM (2004). "Prulifloxacin". Drugs 64 (19): 2221–34; discussion 2235–6. PMID 15456336.
|